This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delanian, S. Articles by Lefaix, J.-L. Search for Related Content PubMed PubMed Citation Articles by Delanian, S. Articles by Lefaix, J.-L. Social Bookmarking                            What's this?

Striking Regression of Chronic Radiotherapy Damage in a Clinical Trial of Combined Pentoxifylline and Tocopherol

From the Service d'Oncologie-Radiothérapie, Hôpital Saint-Louis, Paris; and the Laboratoire de Radiobiologie et d'Etude du Génome, Direction des Sciences du Vivant, Commissariat a l'Energie Atomique, Saclay, France.

Address reprint requests to S. Delanian, MD, PhD, Service d'Oncologie-Radiothérapie, Hôpital Saint Louis, 1, Ave Claude Vellefaux, 75010 Paris, France; email delanian{at}chu-stlouis.fr

PURPOSE: Radiation-induced fibrosis (RIF) remains the most morbid complication of radiotherapy because of the absence of spontaneous regression and the difficulty of patient management. RIF treatment with combined pentoxifylline (PTX) and tocopherol (Vit E) was prompted by recent advances in cellular and molecular biology that have improved researchers' understanding of radiation-induced late-injury mechanisms and by the excellent results from our previous human and animal studies.

PATIENTS AND METHODS: Forty-three patients (mean [± SD] age, 59 ± 10 years) presenting with 50 symptomatic RIF areas involving the skin and underlying tissues were treated from April 1995 to September 1997. Patients had had radiotherapy for head and neck or breast cancer a mean period of 8.5 ± 6.5 years previously. RIF developed in the first year after irradiation and gradually worsened, without spontaneous regression. The mean measurable surface area of RIF ([S]) at the time of this study ([S₀]) was 42 ± 34 cm². The initial Subjective Objective Medical management and Analytic (SOMA) injury evaluation score was 13.2 ± 5.9 and included evidence of edema, plexitis, restricted movement, and local inflammatory signs. A combination of PTX (800 mg/d) and Vit E (1,000 IU/d) was administered orally for at least 6 months.

RESULTS: Treatment was well tolerated. All assessable injuries exhibited continuous clinical regression and functional improvement. Mean RIF surface area and SOMA scores improved significantly (P < .0001) at 3 months ([S₃], -39%; [SOMA₃], -22%), 6 months ([S₆], -53%; [SOMA₆], -35%), and 12 months ([S₁₂], -66%; [SOMA₁₂], -48%), and mean linear dimensions ([D]) diminished from the start of the study ([D₀], 6.5 ± 2.5 cm) to the end of treatment 12 months later ([D₁₂], 4 ± 2 cm). At the time of the treatment, we did not attempt to achieve the maximum effect, and the study was continued.

CONCLUSION: The PTX-Vit E combination reversed human chronic radiotherapy damage and, because no other treatment is presently available for RIF, should be considered as a therapeutic measure.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V Haydont, C Bourgier, and M-C Vozenin-Brotons Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity Br. J. Radiol., September 1, 2007; 80(Special_Issue_1): S32 - S40. [Abstract] [Full Text] [PDF]

				B. Szotowski, S. Antoniak, P. Goldin-Lang, Q.-V. Tran, K. Pels, P. Rosenthal, V. Y. Bogdanov, H.-H. Borchert, H.-P. Schultheiss, and U. Rauch Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells Cardiovasc Res, March 1, 2007; 73(4): 806 - 812. [Abstract] [Full Text] [PDF]

				S. Delanian, R. Porcher, J. Rudant, and J.-L. Lefaix Kinetics of Response to Long-Term Treatment Combining Pentoxifylline and Tocopherol in Patients With Superficial Radiation-Induced Fibrosis J. Clin. Oncol., December 1, 2005; 23(34): 8570 - 8579. [Abstract] [Full Text] [PDF]

				I. Bairati, F. Meyer, M. Gelinas, A. Fortin, A. Nabid, F. Brochet, J.-P. Mercier, B. Tetu, F. Harel, B. Abdous, et al. Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients J. Clin. Oncol., August 20, 2005; 23(24): 5805 - 5813. [Abstract] [Full Text] [PDF]

				D. Azria, A. Pelegrin, J.-B. Dubois, R.-O. Mirimanoff, and M. Ozsahin Radiation Therapy and Tamoxifen: Concurrent or Sequential? It's No Longer the Question! J. Clin. Oncol., June 20, 2005; 23(18): 4239 - 4241. [Full Text] [PDF]

				T. B Chiao and A. J Lee Role of Pentoxifylline and Vitamin E in Attenuation of Radiation-Induced Fibrosis Ann. Pharmacother., March 1, 2005; 39(3): 516 - 522. [Abstract] [Full Text] [PDF]

				C. Borek Dietary Antioxidants and Human Cancer Integr Cancer Ther, December 1, 2004; 3(4): 333 - 341. [Abstract] [PDF]

				C. Borek Antioxidants and Radiation Therapy J. Nutr., November 1, 2004; 134(11): 3207S - 3209S. [Full Text] [PDF]

				H. A. Norman, R. R. Butrum, E. Feldman, D. Heber, D. Nixon, M. F. Picciano, R. Rivlin, A. Simopoulos, M. J. Wargovich, E. K. Weisburger, et al. The Role of Dietary Supplements during Cancer Therapy J. Nutr., November 1, 2003; 133(11): 3794S - 3799. [Abstract] [Full Text] [PDF]

				S. Delanian, R. Porcher, S. Balla-Mekias, and J.-L. Lefaix Randomized, Placebo-Controlled Trial of Combined Pentoxifylline and Tocopherol for Regression of Superficial Radiation-Induced Fibrosis J. Clin. Oncol., July 1, 2003; 21(13): 2545 - 2550. [Abstract] [Full Text] [PDF]

				S Delanian and J-L Lefaix Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate Br. J. Radiol., May 31, 2002; 75(893): 467 - 469. [Abstract] [Full Text] [PDF]

				N. Ledee-Bataille, F. Olivennes, J-L. Lefaix, G. Chaouat, R. Frydman, and S. Delanian Combined treatment by pentoxifylline and tocopherol for recipient women with a thin endometrium enrolled in an oocyte donation programme Hum. Reprod., May 1, 2002; 17(5): 1249 - 1253. [Abstract] [Full Text] [PDF]

				J. Goffin, H. Kreisman, and V. Sandor Bleomycin-Induced Lung Toxicity and Pentoxifylline J. Clin. Oncol., January 15, 2001; 19(2): 597 - 598. [Full Text] [PDF]